Conrelax

Quick links to important sections

Conrelax

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Conrelax

What is Conrelax? Defining the Medicine and its Form

Property Description
Active ingredient Cyclobenzaprine Hydrochloride
Form Oral Tablet or Capsule
Pharmacological class Centrally Acting Skeletal Muscle Relaxant
Common use Short-term management of acute muscle spasms
Origin Synthetic Chemical Compound

Conrelax is an orally administered medication used primarily as a supportive therapy to provide general relief from muscle discomfort and mild pain associated with acute, painful musculoskeletal conditions. Its active ingredient, Cyclobenzaprine, is clinically recognized for its role as a centrally acting skeletal muscle relaxant. It is typically supplied in commercial forms such as an immediate- or extended-release tablet or capsule.

This medication is often prescribed in conjunction with rest and physical therapy. This approach is suitable for short-term use in reducing symptoms of acute muscle spasm. It is indicated that Conrelax provides reliable relief from discomfort during the initial recovery period.

The Core Components: What is Conrelax Made Of?

Conrelax is composed of a synthetic chemical compound, Cyclobenzaprine hydrochloride, meaning its active components are manufactured chemically to ensure high purity and consistency. This differentiates it from naturally derived muscle relaxants available on the market.

The active ingredient affects the central nervous system to reduce muscle overactivity, which is its primary therapeutic action. The key takeaway is that the medicine works by targeting the nerve signals that cause muscles to involuntarily tighten.

What is Conrelax Used For? General Therapeutic Purpose

The general therapeutic purpose of Conrelax is the short-term symptomatic management of acute muscle spasms in adults. It is intended to alleviate the pain and stiffness that result from these spasms, improving overall comfort and enabling a patient to participate more fully in their prescribed physical rehabilitation.

Its role is supportive; it is a medication for managing symptoms, not for curing the underlying cause of the muscle disorder. It aims to break the cycle of pain and involuntary muscle tightening that can hinder a quick and effective recovery.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Conrelax?

Possible Side Effects and Safety Information

The official safety profile for Conrelax (Cyclobenzaprine) establishes its risks based on frequency and affected physiological systems, consistent with regulatory standards. The adverse reactions are primarily categorized as follows:


Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions identified in controlled clinical studies are classified as Very Common (ge 10%) and include drowsiness (somnolence) and dry mouth (xerostomia). Effects classified as Common (1% to 10%) generally involve the central nervous system and the gastrointestinal system, and may include dizziness, fatigue, headache, constipation, and nausea.

Serious Safety Concerns and Contraindications

Regulatory documents report the potential for serious reactions, including the development of Serotonin Syndrome, particularly when Conrelax is used in combination with other serotonergic drugs. The medication is structurally related to tricyclic antidepressants, and associated serious adverse cardiovascular events (e.g., arrhythmias, heart block) have been reported.

Conrelax is contraindicated in patients with a known hypersensitivity to any component, concomitant use with MAO inhibitors (or within 14 days), hyperthyroidism, the acute recovery phase of a myocardial infarction, or certain underlying cardiac issues (e.g., heart block, congestive heart failure).

Population-Specific Safety Notes

Specific considerations are noted for certain groups. The extended-release form is generally not recommended for older adults due to potential for higher plasma concentrations and increased susceptibility to sedation and confusion. Use in individuals with moderate to severe hepatic impairment is not recommended. Safety and effectiveness have not been established for the pediatric population under 15 years of age. Additionally, withdrawal symptoms have been reported upon abrupt discontinuation after prolonged use.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Scope

The most common manifestations officially associated with an overdose of Conrelax are drowsiness and tachycardia (rapid heart rate). Other clinical signs documented in regulatory sources include confusion, dizziness, agitation, tremor, and hallucinations. Overdosage primarily affects the Central Nervous System (CNS) and the Cardiovascular system.

Severity Classification Examples of Critical Manifestations
Life-Threatening Risk Cardiac arrest, severe hypotension, seizures, and coma.
Syndromic Risk Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS)-like features.

Emergency Actions and Monitoring

Immediate medical attention is required for any suspected overdose. Due to the potential for severe effects to develop rapidly, hospital monitoring is necessary as soon as possible. Physicians are advised to contact a poison control center for current guidance, as the management of overdose is complex.

Monitoring and Supportive Measures

Treatment is officially defined as symptomatic and supportive. Because no specific antidote is known, continuous ECG monitoring is required due to the risk of cardiotoxicity, particularly in large ingestions. Overdose severity and risk of fatal outcomes are higher in cases involving multiple drug ingestion (e.g., with alcohol) and in elderly patients.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by listing severe cardiovascular and neurological effects, mandating that the occurrence of these manifestations requires immediate emergency medical attention. The official context for treatment is the absence of a specific antidote, which structurally dictates the necessity for supportive management and continuous ECG monitoring in a hospital setting. The requirement to seek urgent help is triggered by the potential for these regulator-documented life-threatening complications.

Therapeutic Uses of Conrelax

What Conrelax Treats: Main Uses and Benefits

Conrelax is generally used to offer supportive relief and helps ease the overall symptom burden in situations involving certain distressing symptoms. Medications in this category are recognized for their role in the management of symptoms associated with acute musculoskeletal conditions. It is relevant in contexts marked by increased discomfort or tension and is applicable within clinical settings that involve acute or disruptive symptom patterns.

The medication may assist with symptoms related to physical discomfort, heightened physiological activity, and those that interfere with daily functioning. This includes managing pronounced discomfort and supporting stability during periods of functional strain. “It offers symptomatic relief that helps patients cope more steadily with difficult episodes.” Conrelax is considered relevant when supportive symptom management is appropriate, especially during acute episodes, where symptom clusters become intense or disruptive, or in situations involving recurrent manifestations. It provides supportive relief when symptoms interfere with routine activities.


Quick Fact: Symptomatic Support Conrelax is relevant in conditions characterized by periods of heightened symptoms and contexts where short-term symptomatic assistance may be appropriate.

Eligibility and Restrictions for Use

The eligibility profile for Conrelax (Cyclobenzaprine) is strictly defined by official regulatory documents, creating specific exclusions and restrictions for certain patient populations.

Absolute Contraindications (Must Not Use)

Use is formally contraindicated in patients with a known hypersensitivity to the drug or who are concurrently taking Monoamine Oxidase (MAO) inhibitors or have taken them within the past 14 days. The medicine is also prohibited for individuals with hyperthyroidism or serious cardiovascular conditions, including arrhythmias, heart block, congestive heart failure, or those in the acute recovery phase of a myocardial infarction.

Restricted and Conditional Use

Population Group Regulatory Status
Age (Pediatric) Safety not established in children under 15 years old.
Age (Geriatric) Use is not recommended in older adults (ge 65 years) due to increased plasma concentration.
Organ Function Not recommended for patients with moderate to severe hepatic impairment.
Organ Function Use with caution in patients with mild hepatic impairment.
Other Conditions Caution is advised for those with a history of urinary retention or angle-closure glaucoma.
Time Limit Use is not recommended for periods longer than two or three weeks.

Pregnancy and Lactation

For pregnant women, use is advised only if clearly needed, as adequate human studies are lacking (Pregnancy Category B). Caution is recommended while breastfeeding, as it is unknown whether the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Conrelax (Cyclobenzaprine) establishes specific restrictions and risks based on co-administration with other substances that affect the central nervous system. These documented patterns focus on preventing severe pharmacodynamic interactions and managing altered exposure in certain patient groups.

Contraindicated Combinations and Restrictions

Combination Interaction Outcome Separation Requirement
Monoamine Oxidase Inhibitors (MAOIs) (including Linezolid) Contraindicated combination due to risk of serious, potentially fatal reactions. Must not be administered within 14 days of discontinuing an MAOI.
Alcohol (Ethanol) Enhancement of effects resulting in increased CNS depression. Restricted due to additive pharmacodynamic effects.

Documented Pharmacodynamic and Exposure Risks

Co-administration with other Serotonergic Drugs, such as SSRIs, SNRIs, and Tramadol, carries the documented risk of developing Serotonin Syndrome due to additive activity.

The use of CNS Depressants (e.g., barbiturates, opioid medications) with Conrelax can lead to the enhancement of effects, specifically heightened central nervous system depression. Additionally, combining with Anticholinergic Agents may increase the incidence of anticholinergic side effects.

A specific population-dependent note is that patients with Hepatic Impairment exhibit increased plasma concentrations of cyclobenzaprine, which is a consideration related to metabolic clearance.

Mechanism of Action

How Conrelax Works

Conrelax's mechanism of action involves the central nervous system, with a primary focus on structures in the spinal cord and brainstem. The drug functions by modulating key inhibitory neurotransmitter systems: it acts as a positive allosteric modulator at GABA-A receptors and as an agonist at Glycine receptors.

This molecular interaction enhances the activity of the body's natural inhibitory neurotransmitters, leading to an increased influx of chloride ions into the post-synaptic neuron. The resulting hyperpolarization decreases the membrane excitability of the nerve cells, specifically within the inhibitory spinal reflex pathways. This cascade dampens the firing rate of alpha motor neurons, thereby reducing the efferent signaling output from the spinal cord to the skeletal musculature. This targeted physiological modulation results in a shift toward a lower overall muscle tone and lessened motor nerve hyperexcitability.

Dosage and Administration Information

The medicine Conrelax is approved solely for oral administration and is available as an immediate-release (IR) tablet and an extended-release (ER) capsule. Its usage protocol is strictly defined by the dosage form and is indicated for use as an adjunct to rest and physical therapy. The duration of use is explicitly limited to short periods, typically not exceeding two to three weeks.

The dosing regimen varies based on the formulation. The standard adult dosing for the IR tablet is 5 mg taken three times daily, which may be increased to 10 mg three times daily, leading to a maximum daily dose of 30 mg. This form requires administration multiple times throughout the day. Conversely, the ER capsule is administered once daily at an initial dose of 15 mg, with an option to increase to 30 mg daily. The capsule can be taken with or without food.

Administration of the ER capsule requires specific handling: it must be swallowed intact or the contents may be sprinkled onto soft food, such as applesauce, and immediately swallowed without chewing.

Usage is further structured by age and clinical status. For older adults, the initial dosage of the IR form is typically lower and less frequent. The ER capsule formulation is generally not recommended for geriatric patients or for individuals with moderate-to-severe hepatic impairment.

Recent Clinical Evidence

Research Supporting Use in Acute Muscle Spasm


The primary research for Conrelax has evaluated it in the context of acute, painful muscle spasms, such as those that may occur in the lower back or neck. The research base consists mainly of short-term Randomized Controlled Trials (RCTs) and Meta-analyses. These studies explored how symptoms change over defined time intervals. Researchers examined outcomes related to physical discomfort and daily functioning, including physician and patient ratings of global response and measures of local pain relief.

Findings describe patterns observed in the studies related to short-term changes in these outcomes. The evidence contributes to the broader evidence landscape related to acute episodes. The overall evidence quality is generally described as Moderate.


Observations from Trials in Other Contexts

Research has also explored Conrelax in research contexts beyond its primary indication. For instance, the medication was studied for fibromyalgia, a condition characterized by heightened symptoms and functional limitations. Studies primarily examined patient-reported outcomes related to pain intensity, sleep quality, and fatigue.

Research highlights changes measured during the study period, with findings describing small changes in magnitude in core symptoms. The evidence level for this specific research context appears to be Moderate to High in strength.


Research Gaps and Follow-up Duration

The available evidence consistently focuses on observations during the short-term management of acute muscle spasm, typically over intervals of two weeks or less. This short observation window means that long-term effects are not fully established. Adequate research support for more prolonged use is not established.

Furthermore, the main body of research applies to adults, and data for certain groups, such as older adults, remains insufficient. A review of the evidence highlights that comparative evidence is lacking against a full spectrum of other available treatments.

Frequently Asked Questions (FAQ)

Common questions about Conrelax (FAQ)


Q: How quickly should I expect to notice Conrelax working?

Official information indicates that the immediate-release formulation may begin to work within one hour of administration. Maximum effects of the immediate-release tablet may be reached within approximately four hours.


Q: How long does the effect of a Conrelax dose last?

The effect duration depends on the formulation used. The immediate-release tablet generally lasts for about four to six hours, which is why it is taken multiple times daily. The extended-release capsule is designed to release medication slowly over time, providing effects that may last up to 24 hours.


Q: Does Conrelax cause weight gain or weight loss?

Official product labeling for the drug does not list weight change (gain or loss) as a very common or common adverse reaction observed in controlled clinical studies.


Q: Can Conrelax be taken with common pain relievers like ibuprofen?

The official prescribing information does not list a specific drug interaction between cyclobenzaprine and nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Because combining medications can increase complexity, it is important that a health professional reviews all co-administered substances.


Q: What's the difference between Conrelax and other common medications for similar conditions?

Studies and official information indicate that comparative evidence against the full range of other similar treatments is currently lacking. Research has focused primarily on measuring the medication's effect against a placebo, rather than directly comparing it to other muscle relaxants.


Q: Can Conrelax affect my ability to drive or operate machinery?

Due to the potential for significant drowsiness, dizziness, and impairment, individuals are advised to exercise caution or avoid driving or operating hazardous machinery. This advisory applies until a person knows precisely how the medication affects their individual reaction time and physical response.


Q: Can someone with kidney problems use Conrelax?

Official documents state that the drug is primarily processed and eliminated by the kidney. Caution is advised for individuals with mild renal impairment (mild kidney problems). Patients with kidney impairment may require careful monitoring.


Q: Does Conrelax show up on a standard drug screening test?

Cyclobenzaprine is not generally included in standard drug screening panels, such as a basic 5-panel test. However, specific, more comprehensive drug tests can detect the medication if they are looking for it.


Q: What happens if I forget to take a dose of Conrelax?

Official safety instructions define the protocol for a missed dose. Generally, if a dose is missed, a person should adhere to the predetermined schedule and not take an extra or double dose to compensate.


Q: Is there a generic version of Conrelax available?

Yes, the active ingredient in Conrelax, Cyclobenzaprine, is widely available in generic form. These generic options are available as both tablets and extended-release capsules, in addition to brand-name products.


Q: Do food or drinks affect how Conrelax is absorbed?

Official information states the extended-release capsule is labeled to be administered either with or without food. Documentation for the immediate-release tablet does not specify a requirement to take it alongside food.


Q: Is Conrelax habit-forming or addictive?

Cyclobenzaprine is not classified as a controlled substance by the DEA or other regulatory bodies. Official information indicates that the drug is not considered to have the physically addictive or abuse properties associated with opioids or benzodiazepines.


Q: Can I use Conrelax if I have high blood pressure?

This medication is structurally related to tricyclic antidepressants, which can cause serious cardiovascular events. Caution is advised for people with underlying heart conditions, and the drug is contraindicated (prohibited) in specific serious cardiac conditions, such as heart block or congestive heart failure.


Q: Why is Conrelax sometimes prescribed for conditions not listed as its main use?

The medicine is sometimes explored in clinical studies for contexts beyond its primary indication of acute muscle spasm, with research including conditions such as fibromyalgia.


Q: Can Conrelax be used safely alongside birth control pills?

Official product information notes that the use of cyclobenzaprine alongside certain oral contraceptives that contain a hormone called ethinyl estradiol may cause an increase in the blood levels of cyclobenzaprine.


Q: How soon after stopping Conrelax can I start another medicine?

The time it takes for a medicine to be eliminated from the body depends on its half-life. Cyclobenzaprine has a relatively long half-life, and the time required for its full clearance can range from approximately 5.5 to 16.5 days, depending on individual factors.


Q: What should I do if a side effect of Conrelax feels severe?

The safety information specifies that individuals should contact emergency medical services immediately if they experience signs of a serious allergic reaction or a drug overdose. The label instructs that other serious symptoms, such as fast heartbeats or signs of Serotonin Syndrome, should be reported promptly to a healthcare provider who can offer direction.


Q: What are the common reasons why a patient might stop using Conrelax?

Reasons documented in the regulatory label that require or lead to discontinuation include reaching the maximum recommended treatment duration (2–3 weeks). Other reasons involve the occurrence of contraindicated conditions (e.g., cardiac issues) or experiencing severe adverse reactions.


Q: What is the approved age range for using Conrelax?

Official safety and effectiveness have not been established for the pediatric population under 15 years of age. Use of the drug is generally not recommended for older adults aged 65 years and above.


Q: Does Conrelax interact with herbal supplements like St. John's Wort?

The label states that caution is necessary when the drug is used alongside other Serotonergic Drugs, a class that includes certain herbal supplements. This is due to a documented risk of Serotonin Syndrome if co-administered.


Q: What is the general success rate mentioned in clinical trials for Conrelax?

Clinical studies primarily focus on short-term changes in symptoms. Evidence describes patterns of improvement in outcomes like local pain relief and global response during the initial recovery period.


Q: Is the medication meant to be taken regularly or only when needed?

The medication is prescribed to be taken according to a defined, fixed dosing schedule. It is not intended to be used on an as-needed (PRN) basis.


Q: Why is it important to share a full list of medications with the doctor before starting Conrelax?

Sharing a full list is essential for the healthcare provider to review and manage potential risks. This is required to avoid severe, contraindicated combinations (such as with MAOIs) and to manage the documented risk of enhanced central nervous system depression or Serotonin Syndrome.

How should Conrelax be stored and disposed of?

Official Storage and Disposal Requirements

Conrelax (Cyclobenzaprine) must be stored according to strict regulatory guidelines to maintain its stability. The product requires storage at controlled room temperature, specifically maintained between 20 C and 25 C (68 F and 77 F). The medication must be kept in its original container, tightly closed, and protected from moisture.

Child Safety and Handling:

Storage rules require that this medicine, like all medications, must be kept out of the sight and reach of children.

Disposal Instructions:

Unused or expired Conrelax must not be flushed down a toilet or poured into a drain. Disposal should follow established drug take-back programs or involve securing the medicine (mixed with an unpalatable substance) in a sealed bag before placing it in the household trash, in line with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Conrelax found in:

A-Z Index: